BioSpace News Archive

CooperCompanies, will participate in the 2020 Wells Fargo Virtual Healthcare Conference, on September 10, 2020.

Completion of Dosing in Phase 1 Multiple Ascending Dose Study (“MAD”) of RGLS4326 in Healthy Volunteers for Autosomal Dominant Polycystic Kidney Disease (“ADPKD”) FDA Orphan Designation of RGLS4326 for ADPKD Appointment of Denis Drygin, Ph.D., as Chief Scientific Officer [13-August-2020] LA JOLLA, Calif. , Aug. 13, 2020 /PRNewsw

Test Volumes Improved Meaningfully By the End of the Fourth Quarter Following Substantial Declines in March and April Due to the Initiation of Social Distancing Policies Total Fourth-Quarter Revenues of $93.2 Million Fourth-Quarter Diluted EPS of ($0.74) and Adjusted EPS of ($0.31) SALT LAKE CITY, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced financia

Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months ended June 30, 2020. The first quarter of fiscal 2020 saw the Company achieve a number of significant operational milestones as it embarked on the build out of both its commercial and market access teams and completed enrollment in the Phase 2a study of vibegron for irritable bowel syndrome (IBS) pain.

Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2020, as well as recent operational highlights. “We set out in 2016 to become the leading precision oncology company focused on syn

Total Revenues Increase 208.6%; Gross Profit Increases 245.2%; Net Loss Narrowed Significantly Company Completes Accretive Acquisition of Mesa Organics and Drives Value to the Bottom Line Company to Host Conference Call and Webcast Today at 4:30 p.m. ET DENVER--( BUSINESS WIRE )-- Schwazze, formerly operating as Medicine Man Technologies Inc. (OTCQX: SHWZ) (“Schwazze " or “the Company”), today announced financial results for its second

Shineco, Inc. announced that the Company’s common stock will trade on a split-adjusted basis following the implementation of a reverse stock split at the ratio of one-for-nine shares on The Nasdaq Capital Market effective with the open of the market on Monday, August 17, 2020.

SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today provided a business update and reported financial results for the quarter ended June 30, 2020.

Grand River Aseptic Manufacturing, a leading parenteral contract development and manufacturing organization, was recognized in Inc. Magazine’s Inc. 5000 list for the fourth consecutive year.

Entered into two new collaborations with top tier animal health companies Entered into a fully funded human health collaboration with a top five global pharmaceutical company Started an animal trial for SARS-CoV-2 RBD vaccine candidate in Israel and another animal trial in European is expected to begin soon